Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Multiple Myeloma 13Neoplasms, Plasma Cell 3Recurrence 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of Lung 2Waldenstrom Macroglobulinemia 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Polyneuropathies 1Paraproteinemias 1Mouth Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Endocrine System Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Temozolomide 17Radiotherapy 5Bevacizumab 5Filgrastim 4vocimagene amiretrorepvec 3sargramostim 3etoposide phosphate 3antineoplaston AS 2-1 3antineoplaston A10 3Surgical Procedures, Operative 3O(6)-benzylguanine 3Melphalan 3Lomustine 3Flucytosine 3Dynamic Contrast Enhanced Magnetic Resonance Imaging 3Carmustine 3Aminolevulinic Acid 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tovorafenib 2palbociclib 2cabozantinib 2Vorinostat 2Topotecan 2Thiotepa 2Radiotherapy, Intensity-Modulated 2Perfusion Magnetic Resonance Imaging 2Magnetic Resonance Spectroscopy 2Irinotecan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Astrocytoma × Thalidomide × Clear all
NCT00014443 2023-01-09

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Rush University Medical Center

Phase 2 Terminated
5 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡